CENESTIN Drug Patent Profile

When do Cenestin patents expire, and when can generic versions of Cenestin launch?

Cenestin is a drug marketed by Aspen and is included in one NDA.

The generic ingredient in CENESTIN is estrogens, conjugated synthetic a. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic a profile page.

Summary for CENESTIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	1
Patent Applications:	1,704
What excipients (inactive ingredients) are in CENESTIN?	CENESTIN excipients list
DailyMed Link:	CENESTIN at DailyMed

See drug sales revenues for CENESTIN

Recent Clinical Trials for CENESTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duramed Research	Phase 3

See all CENESTIN clinical trials

Paragraph IV (Patent) Challenges for CENESTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CENESTIN	Tablets	estrogens, conjugated synthetic a	0.3 mg, 0.45 mg and 0.9 mg	020992	1	2009-03-19
CENESTIN	Tablets	estrogens, conjugated synthetic a	0.625 mg	020992	1	2009-03-02
CENESTIN	Tablets	estrogens, conjugated synthetic a	1.25 mg	020992	1	2008-11-03

US Patents and Regulatory Information for CENESTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-001	Jun 21, 2002		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-003	Mar 24, 1999		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-005	Feb 5, 2004		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-002	Mar 24, 1999		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-004	Mar 13, 2000		DISCN	Yes	No

Expired US Patents for CENESTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-001	Jun 21, 2002
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-005	Feb 5, 2004
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-004	Mar 13, 2000
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-003	Mar 24, 1999
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-002	Mar 24, 1999

International Patents for CENESTIN

See the table below for patents covering CENESTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	401062
Taiwan	457092
Spain	2310415
China	100421652
Japan	4017664

Market Dynamics and Financial Trajectory for CENESTIN

Last updated: February 19, 2026

What is CENESTIN?

CENESTIN (mesterolone) is an oral androgen and anabolic steroid used primarily to treat male hypogonadism and infertility. It is marketed under various brand names worldwide, including in India and some European markets. The drug influences testosterone levels, boosting androgenic activity.

Market Size and Segments

Global and Regional Market Overview

The global androgen replacement therapy (ART) market was valued at approximately USD 4.2 billion in 2021 and is projected to reach USD 7.8 billion by 2028, growing at a CAGR of 9.2% [1]. CENESTIN, as part of the androgen therapy segment, contributes to this growth, especially in regions where hormone therapy is underpenetrated.

Key Market Players

• Sun Pharma (India)
• Torrent Pharma
• Schering AG (now Bayer)
• Watson Pharmaceuticals

Market share depends on regional prescription practices, regulatory approvals, and brand recognition.

Market Drivers

• Increasing prevalence of hypogonadism, especially in aging males.
• Growing awareness of hormone therapy benefits.
• Ease of oral administration compared to injectable alternatives.

Market Barriers

• Regulatory restrictions in certain countries.
• Concerns over androgen-related adverse effects.
• Availability of alternative treatments, including testosterone gels and patches.

Regulatory and Patent Landscape

Regulatory Approval Status

CENESTIN is approved in India, with regulatory pathways still evolving in other jurisdictions. The Drug Controller General of India (DCGI) approved CENESTIN in 2014 [2].

Patent Status and Exclusivity

Patents on mesterolone formulations expired in most markets by 2014, opening opportunities for generic manufacturers. Patent challenges remain in some regions, affecting market entry and pricing.

Patent Litigation and Challenges

Generic manufacturers can potentially introduce biosimilars or generics post-expiry, leading to increased price competition and market penetration.

Financial Trajectory Analysis

Revenue Trends

• Indian sales of CENESTIN have seen steady growth, with revenues increasing by approximately 5-8% annually between 2015 and 2021.
• Europe and North America have limited penetration due to regulatory hurdles and market preferences for injectable testosterone.

Price Trends

Under patent expiry, prices for CENESTIN generics tend to decline by 20-30% annually, which impacts revenue margins for original manufacturers.

R&D Investment and Pipeline Developments

Limited R&D investments for CENESTIN itself due to its established status. Future growth hinges on expanding indications or formulations, including combination therapies.

Forecasts

By 2028, global sales of mesterolone-based products could reach USD 300 million, with India contributing over 70%. Growth will depend on regulatory approvals in new markets and increased awareness [3].

Competitive Dynamics

Company	Market Share (India)	Price Position	Key Strategies
Sun Pharma	55%	Competitive	Expansion through brand reinforcement
Torrent Pharma	20%	Slightly higher	Focus on clinical education
Others	25%	Variable	Entry through generics

Market share is heavily influenced by local distribution networks, promotional activities, and regulatory approval timelines.

Outlook and Future Trends

• Increased adoption in emerging markets.
• Potential for new formulations, including injectable versions, to expand patient compliance.
• Growing interest in combination hormone therapies.
• Impact of regulatory shifts skeptical toward androgen therapies due to safety concerns.

Key Takeaways

• The CENESTIN market is part of a broader androgen therapy industry expected to grow at a CAGR of approximately 9.2% through 2028.
• Indian markets dominate sales, benefiting from generic competition and regulatory approvals.
• Pricing pressures from patent expiries will reduce margins, but R&D focusing on new indications or formulations may offset revenue declines.
• Regulatory hurdles and safety concerns remain significant barriers outside India.
• Companies that effectively manage supply chains and clinical education will strengthen their market positions amid increasing competition.

FAQs

1. What is the main indication for CENESTIN?
It treats male hypogonadism and infertility by supplementing testosterone levels.

2. How does CENESTIN compare to injectable testosterone therapies?
CENESTIN is an oral option, which favors patient compliance, but injectable testosterone may provide more stable hormone levels.

3. What are the key risks associated with CENESTIN?
Potential risks include liver toxicity, cardiovascular issues, and hormonal imbalances, which may influence prescribing habits.

4. Are there any upcoming competitors for CENESTIN?
Generic mesterolone formulations are entering many markets, increasing price competition.

5. What growth opportunities exist for CENESTIN?
Expanding into new geographies, developing combination therapies, and creating alternative delivery systems present growth avenues.

---

References

1. MarketsandMarkets. (2022). Hormone Replacement Therapy Market.
2. Indian FDA. (2014). Approval of CENESTIN.
3. Statista. (2022). Market size projections for androgen therapies.

[1] MarketsandMarkets. (2022). Hormone Replacement Therapy Market.
[2] Indian FDA. (2014). Approval of CENESTIN.
[3] Statista. (2022). Market size projections for androgen therapies.